Primary central nervous system lymphoma

Critical Reviews in Oncology/Hematology

Volumn 63, Issue 3, 2007, Pages 257-268

  Ferreri, Andrés J M ^a   Reni, Michele ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Cerebrospinal fluid; Methotrexate; PCNSL; Radiotherapy; Rituximab; Temozolomide

Indexed keywords

BUSULFAN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; PROCARBAZINE; RITUXIMAB; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROSPINAL FLUID; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG MEGADOSE; HUMAN; IMAGE ANALYSIS; LETHALITY; LYMPHOMA; NEUROIMAGING; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIATION DOSE; REVIEW; RISK FACTOR; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME;

CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; LYMPHOMA; PROGNOSIS;

EID: 34547162391     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2007.04.012     Document Type: Review

References (88)

1. Henry J.M., Heffner R.R.J., Dillard S.H., Earle K.M., and Davis R.L. Primary malignant lymphomas of the central nervous system. Cancer 34 (1974) 1293-1302
2. Hochberg F.H., and Miller D.C. Primary central nervous system lymphoma. J Neurosurg 68 (1988) 835-853
3. Jellinger K.A., and Paulus W. Primary central nervous system lymphomas-new pathological developments. J Neurooncol 24 (1995) 33-36
4. Greig N.H., Ries L.G., Yancik R., and Rapoport S.I. Increasing annual incidence of primary malignant brain tumors in the elderly. J Natl Cancer Inst 82 (1990) 1621-1624
5. Eby N.L., Grufferman S., Flannelly C.M., et al. Increasing incidence of primary brain lymphoma in the US. Cancer 62 (1988) 2461-2465
6. Kadan-Lottick N.S., Skluzacek M.C., and Gurney J.G. Decreasing incidence rates of primary central nervous system lymphoma. Cancer 95 (2002) 193-202
7. Fine H.A., and Mayer R.J. Primary central nervous system lymphoma. Ann Intern Med 119 (1993) 1093-1104
8. Ferreri A.J., Reni M., and Villa E. Primary central nervous system lymphoma in immunocompetent patients. Cancer Treat Rev 21 (1995) 415-446
9. Blumenthal D.T., Raizer J.J., Rosenblum M.K., et al. Primary intracranial neoplasms in patients with HIV. Neurology 52 (1999) 1648-1651
10. Ng V.L., and McGrath M.S. The immunology of AIDS-associated lymphomas. Immunol Rev 162 (1998) 293-298
11. O'Neill B.P., O'Fallon J.R., Colgan J.P., and Earle J.D. Primary CNS non-Hodgkin's lymphoma (PCNSL): survival advantage with combined initial therapy. Fourth international congress on anti-cancer chemotherapy. Paris, France, February 2-5 (1993) 119 [meeting abstract]
12. Deangelis L.M. Primary central nervous system lymphoma as a secondary malignancy. Cancer 67 (1991) 1431-1435
13. Lachance D.H., O'Neill B.P., Macdonald D.R., et al. Primary leptomeningeal lymphoma: report of 9 cases, diagnosis with immunocytochemical analysis, and review of the literature. Neurology 41 (1991) 95-100
14. Bergmann M., Terzija-Wessel U., Blasius S., et al. Intravascular lymphomatosis of the CNS: clinicopathologic study and search for expression of oncoproteins and Epstein-Barr virus. Clin Neurol Neurosurg 96 (1994) 236-243
15. Marshall A.G., Pawson R., Thom M., et al. HTLV-I associated primary CNS T-cell lymphoma. J Neurol Sci 158 (1998) 226-231
16. Bashir R., McManus B., Cunningham C., Weisenburger D., and Hochberg F. Detection of Eber-1 RNA in primary brain lymphomas in immunocompetent and immunocompromised patients. J Neurooncol 20 (1994) 47-53
17. Jellinger K.A., and Paulus W. Primary central nervous system lymphomas-an update. J Cancer Res Clin Oncol 119 (1992) 7-27
18. Hacker S.M., Knight B.P., Lunde N.M., et al. A primary central nervous system T cell lymphoma in a renal transplant patient. Transplantation 53 (1992) 691-692
19. Schaumburg H.H., Plank C.R., and Adams R.D. The reticulum cell sarcoma-microglioma group of brain tumours. A consideration of their clinical features and therapy. Brain 95 (1972) 199-212
20. Reni M., Ferreri A.J., Garancini M.P., and Villa E. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol 8 (1997) 227-234
21. Kranz B.R., Thierfelder S., Gerl A., and Wilmanns W. Cerebrospinal fluid immunocytology in primary central nervous system lymphoma. Lancet 340 (1992) 727
22. Hu X., Hong B., Wang W., and Lu H. Primary central nervous system lymphoma. A changeable tumor. Chin Med J (Engl) 109 (1996) 414-416
23. Ferreri A.J., Reni M., Pasini F., et al. A multicenter study of treatment of primary CNS lymphoma. Neurology 58 (2002) 1513-1520
24. Shenkier T.N., Blay J.Y., O'Neill B.P., et al. Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol 23 (2005) 2233-2239
25. Camilleri-Broet S., Criniere E., Broet P., et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 107 (2006) 190-196
26. Deangelis L.M. Primary central nervous system lymphoma. Recent Results Cancer Res 135 (1994) 155-169
27. Levy-Clarke G.A., Chan C.C., and Nussenblatt R.B. Diagnosis and management of primary intraocular lymphoma. Hematol Oncol Clin North Am 19 (2005) 739-749 [viii]
28. Shibata S. Sites of origin of primary intracerebral malignant lymphoma. Neurosurgery 25 (1989) 14-19
29. Reni M., Ferreri A.J., Zoldan M.C., and Villa E. Primary brain lymphomas in patients with a prior or concomitant malignancy. J Neurooncol 32 (1997) 135-142
30. Raizer J.J., Koutcher J.A., Abrey L.E., et al. Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma. J Neurooncol 71 (2005) 173-180
31. Palmedo H., Urbach H., Bender H., et al. FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging 33 (2006) 164-168
32. O'Neill B.P., Dinapoli R.P., Kurtin P.J., and Habermann T.M. Occult systemic non-Hodgkin's lymphoma (NHL) in patients initially diagnosed as primary central nervous system lymphoma (PCNSL): how much staging is enough?. J Neurooncol 25 (1995) 67-71
33. Hayakawa T., Takakura K., Abe H., et al. Primary central nervous system lymphoma in Japan-a retrospective, co-operative study by CNS-Lymphoma Study Group in Japan. J Neurooncol 19 (1994) 197-215
34. Nelson D.F., Martz K.L., Bonner H., et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23 (1992) 9-17
35. Loeffler J.S., Ervin T.J., Mauch P., et al. Primary lymphomas of the central nervous system: patterns of failure and factors that influence survival. J Clin Oncol 3 (1985) 490-494
36. Ferreri A.J., Reni M., Zoldan M.C., Terreni M.R., and Villa E. Importance of complete staging in non-Hodgkin's lymphoma presenting as a cerebral mass lesion. Cancer 77 (1996) 827-833
37. Abrey L.E., Batchelor T.T., Ferreri A.J., et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23 (2005) 5034-5043
38. Jahnke K., Hummel M., Korfel A., et al. Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes. J Clin Oncol 24 (2006) 4754-4757
39. Carbone P.P., Kaplan H.S., Musshoff K., Smithers D.W., and Tubiana M. Report of the Committee on Hodgkin's disease staging classification. Cancer Res 31 (1971) 1860-1861
40. Laperriere N.J., Cerezo L., Milosevic M.F., et al. Primary lymphoma of brain: results of management of a modern cohort with radiation therapy. Radiother Oncol 43 (1997) 247-252
41. Socie G., Piprot-Chauffat C., Schlienger M., et al. Primary lymphoma of the central nervous system. An unresolved therapeutic problem. Cancer 65 (1990) 322-326
42. Deangelis L.M., Yahalom J., Thaler H.T., and Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10 (1992) 635-643
43. Reni M., Ferreri A.J., and Villa E. Second-line treatment for primary central nervous system lymphoma. Br J Cancer 79 (1999) 530-534
44. Panageas K.S., Elkin E.B., Deangelis L.M., Ben Porat L., and Abrey L.E. Trends in survival from primary central nervous system lymphoma. 1975-1999. Cancer 104 (2005) 2466-2472
45. Blay J.Y., Conroy T., Chevreau C., et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 16 (1998) 864-871
46. Ferreri A.J., Blay J.Y., Reni M., et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21 (2003) 266-272
47. Abrey L.E., Deangelis L.M., and Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 16 (1998) 859-863
48. Glass J., Gruber M.L., Cher L., and Hochberg F.H. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 81 (1994) 188-195
49. O'Brien P.C., Roos D.E., Liew K.H., et al. Preliminary results of combined chemotherapy and radiotherapy for non-AIDS primary central nervous system lymphoma. Trans-Tasman Radiation Oncology Group (TROG). Med J Aust 165 (1996) 424-427
50. Cher L., Glass J., Harsh G.R., and Hochberg F.H. Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: preliminary results. Neurology 46 (1996) 1757-1759
51. Blay J.Y., Bouhour D., Carrie C., et al. The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression. Blood 86 (1995) 2922-2929
52. Brada M., Hjiyiannakis D., Hines F., Traish D., and Ashley S. Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma (PCL). Int J Radiat Oncol Biol Phys 40 (1998) 1157-1162
53. Bessell E.M., Graus F., Punt J.A., et al. Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy. J Clin Oncol 14 (1996) 945-954
54. Glick J.H., Kim K., Earle J., and O'Connell M.J. An ecog randomized phase III trial of CHOP vs CHOP + radiotherapy (XRT) for intermediate grade early stage non-Hodgkin's lymphoma (NHL). Proc Annu Meet Am Soc Clin Oncol 14 (1995) 391
55. Sandor V., Stark-Vancs V., Pearson D., et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 16 (1998) 3000-3006
56. Weigel R., Senn P., Weis J., and Krauss J.K. Severe complications after intrathecal methotrexate (MTX) for treatment of primary central nervous system lymphoma (PCNSL). Clin Neurol Neurosurg 106 (2004) 82-87
57. Schultz C., Scott C., Sherman W., et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol 14 (1996) 556-564
58. Batchelor T.T., Kolak G., Ciordia R., Foster C.S., and Henson J.W. High-dose methotrexate for intraocular lymphoma. Clin Cancer Res 9 (2003) 711-715
59. Camilleri-Broet S., Martin A., Moreau A., et al. Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d'etude des Leucenies et Autres Maladies du Sang (GOELAMS). Am J Clin Pathol 110 (1998) 607-612
60. Cheng A.L., Yeh K.H., Uen W.C., et al. Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma: a pilot study of the BOMES protocol. Cancer 82 (1998) 1946-1951
61. Freilich R.J., Delattre J.Y., Monjour A., and Deangelis L.M. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 46 (1996) 435-439 [see comments]
62. Guha-Thakurta N., Damek D., Pollack C., and Hochberg F.H. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol 43 (1999) 259-268 [in process citation]
63. Herrlinger U., Schabet M., Brugger W., et al. German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol 51 (2002) 247-252
64. Batchelor T., Carson K., O'Neill A., et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 21 (2003) 1044-1049
65. Schlegel U., Pels H., Glasmacher A., et al. Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study. J Neurol Neurosurg Psychiatry 71 (2001) 118-122
66. Abrey L.E., Yahalom J., and Deangelis L.M. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18 (2000) 3144-3150
67. Bromberg J.E., Siemers M.D., and Taphoorn M.J. Is a "vanishing tumor" always a lymphoma?. Neurology 59 (2002) 762-764
68. Herrlinger U., Kuker W., Uhl M., et al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 57 (2005) 843-847
69. Nguyen P.L., Chakravarti A., Finkelstein D.M., et al. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 23 (2005) 1507-1513
70. Boiardi A., Silvani A., Pozzi A., et al. Chemotherapy is effective as early treatment for primary central nervous system lymphoma. J Neurol 246 (1999) 31-37
71. Plotkin S.R., Betensky R.A., Hochberg F.H., et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 10 (2004) 5643-5646
72. Galetto G., and Levine A. AIDS-associated primary central nervous system lymphoma. Oncology Core Committee, AIDS Clinical Trials Group. JAMA 269 (1993) 92-93
73. Khalfallah S., Stamatoullas A., Fruchart C., et al. Durable remission of a relapsing primary central nervous system lymphoma after autologous bone marrow transplantation. Bone Marrow Transplant 18 (1996) 1021-1023
74. Abrey L.E., Moskowitz C.H., Mason W.P., et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 21 (2003) 4151-4156
75. Illerhaus G., Marks R., Ihorst G., et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 24 (2006) 3865-3870
76. Soussain C., Suzan F., Hoang-Xuan K., et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 19 (2001) 742-749
77. Varadi G., Or R., Kapelushnik J., et al. Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma. Leuk Lymphoma 34 (1999) 185-190
78. Doolittle N.D., Miner M.E., Hall W.A., et al. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 88 (2000) 637-647
79. Tyson R.M., Siegal T., Doolittle N.D., et al. Current status and future of relapsed primary central nervous system lymphoma (PCNSL). Leuk Lymphoma 44 (2003) 627-633
80. Reni M., Mason W., Zaja F., et al. Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 40 (2004) 1682-1688
81. Dabaja B.S., McLaughlin P., Ha C.S., et al. Primary central nervous system lymphoma: phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy. Cancer 98 (2003) 1021-1028
82. Enting R.H., Demopoulos A., Deangelis L.M., and Abrey L.E. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63 (2004) 901-903
83. Schulz H., Pels H., Schmidt-Wolf I., et al. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 89 (2004) 753-754
84. Fischer L., Thiel E., Klasen H.A., et al. Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan. Neurology 62 (2004) 1885-1887
85. Reni M., Ferreri A.J., Guha-Thakurta N., et al. Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate. Int J Radiat Oncol Biol Phys 51 (2001) 419-425
86. Stewart D.A., Forsyth P., Chaudhry A., et al. High dose thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic stem cell transplantation (ASCT) without whole brain radiotherapy (WBRT) for primary central nervous system lymphoma (PCNSL). Blood 104 (2004) 901
87. Colombat P., Lemevel A., Bertrand P., et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant 38 (2006) 417-420
88. Montemurro M., Kiefer T., Schuler F., et al. Primary CNS lymphoma treated with HD-methotrexate, HD-busulfan/thiotepa autologous stem cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter OSHO-53 phase II. Blood 106 (2005) 934a